Vinpocetine:

Vinpocetine A Superior Cerebral Metabolic Enhancer and Neuroprotector
Ward Dean. M.D. and John Morgenthaler

Vinpocetine is a powerful memory enhancer. It facilitates cerebral metabolism by improving cerebral microcirculation (blood flow), stepping up brain cell ATP production (ATP is the cellular energy molecule), and increasing utilization of glucose and oxygen.

Vinpocetine is a derivative of vincamine, which is an extract of the periwinkle. Although these substances have many similar effects, Vinpocetine has more benefits and fewer adverse effects than vincamine.

What all this means is that Vinpocetine shares many of the effects of several other cognitive enhancers.
Vinpocetine is often used for the treatment of cerebral circulatory disorders such as memory problems, acute stroke, aphasia (loss of the power of expression), apraxia (inability to coordinate movements), motor disorders, dizziness and other cerebro-vestibular (inner-ear) problems, and headache. Vinpocetine is also used to treat acute or chronic ophthalmological diseases of various origin, with visual acuity improving in 70% of the subjects.

Vinpocetine also is used in the treatment of sensorineural hearing impairment.
The Gedeon Richter company of Hungary markets Vinpocetine as Cavinton in Europe. They have funded more than one hundred studies on Vinpocetine, often comparing its effects to other smart drugs. The incidence of side effects in humans using the drug orally is usually less than one percent, with the rare unwanted effects usually disappearing with continued use.

One series of studies that Gedeon Richter conducted involved 882 patients with neurological disorders ranging from stroke to cerebral insufficiency. Significant improvements
were found in 62% of the patients. In one of the studies, cerebral insufficiency patients were asked to memorize a list of 10 words. Without Vinpocetine the subjects were able to memorize an average of 6 words. After a month of treatment the average went up to 10 words. Gedeon Richter promotes Vinpocetine as the only drug that improves cerebral metabolism (glucose and oxygen uptake), tolerance of hypoxia (deficient blood oxygenation), ATP concentration, norepinephrine and serotonin turnover, and cerebral microcirculation. Gedeon Richter also claims that Vinpocetine selectively increases blood flow to the brain, improving blood flow to the impaired area without lowering blood flow to other parts of the body (Gedeon Richter product literature).

As if the medical uses of Vinpocetine were not amazing enough, in one double-blind crossover study normal, healthy volunteers showed incredible short-term memory improvement an hour after taking 40 mg of Vinpocetine. The volunteers took a computer-administered short-term memory test called a Sternberg Memory
Scanning Test. The volunteers (all women between the ages of 25 and 40) were shown one to three digits on a computer screen. Then, a moment later, they were shown a long string of digits. The volunteers then indicated whether any of the first digits appeared in the second long string. The time the volunteer took to remember was then assessed. On a placebo, the women took an average of 700 milliseconds to respond when the first set contained 3 digits. With Vinpocetine, they averaged under 450 milliseconds! 5

Precautions: Adverse effects are rare, but include hypotension, dry mouth, weakness, and tachycardia. Vinpocetine has no drug interactions, no toxicity, and is generally very safe.

Dosage: One ten mg capsule, one to three per day.

Excerpted from Smart Drugs & Nutrients

Reprinted with permission from Smart Publications, Inc.

How did we qualify VRP?

References:
1. DeNoble, V.J., Repetti. S.J., Gelpke, L.W., Wood, L.M., Keim, K.L. Vinpocetine: Nootropic Effects on Scopolamine-lnduced and Hypoxia-Induced Retrieval Deficits of a
Step-Through Passive Avoidance Response in Rats. Pharmacology Biochemistry & Behavior. 1986, Vol. 24, pp. 1123-8.

2. Gedeon Richter product literature, Cavinton.

3. Hadjiev, D., Yancheva, S. Rheoencephalographic and Psychologic Studies with Ethyl Apovincaminate in Cerebral Vascular Insufficiency. Arzneimittelforschung. 1976,
Vol. 26, pp. I 947-50.

4. E., Atarashi, J., Araki, G., Ito, E., Omae, T., Kuzuya, F., Nukada, T., Ebi, O. Comparison of Vinpocetine with Ifenprodil Tartrate and Dihydroergotoxine Mesylate
Treatment and Results of Long-Term Treatment with Vinpocetine. Current Therapeutic Research. 1985, Vol. 37, No. 5, pp. 811-21.

5. Pelton, R., Pelton, T.C. Mind Food & Smart Pills. New York: Doubleday, 1989.

6. Subhan, Z., Hindmarch, I. Psychopharmacological Effects of Vinpocetine in Normal Healthy Volunteers. European Journal of Clinical Pharmacology. 1985, Vol. 28, pp.
567-71.